Advancing healthcare through scientific excellence, advanced manufacturing, and innovation — while contributing to the localization of pharmaceutical production in Saudi Arabia.
Our journey is built on a strong purpose, a passion for excellence, and a commitment to creating a healthier tomorrow.
We continue to grow with innovation, integrity, and impact.
Our Journey
From our foundation in 2013 to becoming a regional leader in pharmaceutical manufacturing, our journey is built on milestones that drive progress and improve lives.

2013
Sudair Pharma was established in February 2013, with a mission to strengthen local pharmaceutical manufacturing and improve patient access to essential therapies.

2016
The foundation stone was laid, and construction began on the first specialized anti-neoplastic and high-potency manufacturing facility.

2017
First anti-neoplastic technology transfer partnership secured, and anti-neoplastic manufacturing plant completed.

2018
First portfolio of 11 products registered into SFDA, with the first anti-neoplastic treatment launched.

2020
Expanded our portfolio to 45 registered products, while entering Bahraini and UAE markets.

2021
Reaching 61 registered products and the localisation of the first anti-neoplastic product, Lenalidomide, completed.

2022
SAP S/4HANA, state-of-the-art enterprise resource management system implemented across operations.

2023
Introduced the first and only sterile high-potent line in the Kingdom and localised the manufacturing of more than 10 pharmaceutical products.

2024
Signed the Kingdom’s first pharmaceutical off-take agreement and launched a major expansion of the Sudair Manufacturing Complex, introduced new products across anti-neoplastic, diabetes, and respiratory therapeutic areas.

2025
Insulin Manufacturing Facility construction initiated and localising 13 products, reaching 35 in total.

2026
Stepped into the biosimilars market. Registered 16 new products, increasing the total registered portfolio to 128 products and reached 39 fully manufactured products at Sudair Pharma facilities.
Guided by a clear purpose and a shared vision, we are committed to improving lives through quality, innovation, and integrity.
We improve lives by localising advanced therapies
Enhancing our community’s access to high-quality medicinal products through our professional team, while localising and developing cutting-edge manufacturing technologies.
Sudair Pharma supports Saudi Vision 2030 by expanding local pharmaceutical manufacturing, developing Saudi talent, and strengthening access to high-quality medicines. Through localisation and innovation, we contribute to a more resilient and sustainable healthcare sector.
Therapeutic Areas
From anti-neoplastic and hematology to respiratory, neurology, cardiometabolic and rare disease therapies — manufactured and supplied to international quality standards.






Advancing
Health.
Transforming
Lives.
On World Diabetes Day, we celebrate another milestone in our journey toward insulin localization in Saudi Arabia.
Sudair Pharma was honored to welcome His Excellency the Minister of Health, Fahad Al-Jalajel, during its participation in the Global Health Exhibition 2025. The visit highlighted the Kingdom’s commitment to strengthening national pharmaceutical manufacturing and advancing a sustainable healthcare system. Several senior officials and leaders also visited the booth, underscoring Sudair Pharma’s growing impact in shaping the future of Saudi healthcare.
Sudair Pharma participated in the Global Health Exhibition 2025, showcasing advanced national pharmaceutical capabilities and highlighting the company’s contribution to strengthening Saudi Arabia’s healthcare ecosystem. The SPC booth attracted significant interest and served as a platform for strategic discussions and industry engagement.